Rapport Therapeutics Target Price

See Rapport Therapeutics's analyst price targets ($67) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$33.83

Average Target Price

$67.00

98% upside

4 analysts in the last 4 months

High: $75 | Low: $52

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-16	BTIGKambiz Yazdi	$75	121.7% upside
2026-08-17	Raymond JamesTiago Fauth	$75	121.7% upside
2026-08-12	H.C. WainwrightDouglas Tsao	$66	95.1% upside
2026-06-24	Leerink Partners	$52	53.7% upside
2026-05-21	BTIG	$65	92.1% upside
2026-05-18	Truist Financial	$56	65.5% upside
2026-04-10	Raymond JamesTiago Fauth	$66	95.1% upside
2026-03-09	BTIGKambiz Yazdi	$47	38.9% upside
2026-02-02	Wells FargoBenjamin Burnett	$43	27.1% upside
2025-12-19	Wells Fargo	$51	50.8% upside
2025-12-09	H.C. WainwrightDouglas Tsao	$40	18.2% upside
2025-09-16	Truist FinancialJoon Lee	$44	30.1% upside
2024-07-02	JefferiesAndrew Tsai	$35	3.5% upside
2024-07-02	Stifel NicolausPaul Matteis	$35	3.5% upside

Rapport Therapeutics (RAPP) FAQ

Rapport Therapeutics (RAPP) currently reports a target price of $67. Use the charts on this page to explore Rapport Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Rapport Therapeutics is $67, about 98.0% upside from the current share price of $33.83. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $67, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rapport Therapeutics, and consider following RAPP for alerts when major investors trade the stock.